AVALO THERAPEUTICS, INC. (AVTX)

SEC filing

AVALO THERAPEUTICS, INC.

AVTX · CIK 1534120

4 · Sep 18, 2026 · Chief Financial Officer Sullivan Christopher Ryan sold 12.39K shares at $16.33/share ($202.4K); exercised options for 24.79K shares

Chief Financial Officer Sullivan Christopher Ryan sold 12.39K shares at $16.33/share ($202.4K); exercised options for 24.79K shares

Filed: Sep 18, 2026
Period: Sep 16, 2026
Accession: 0001810417-26-000023
Filer: Avalo Therapeutics, Inc.

View on SEC.gov All SEC filings

Filing document

xslF345X06/form4-09182026_040901.xml

xslF345X06/form4-09182026_040901.xmlSEC.gov

Other files

Graphics and non-inline formats (not embedded below).

4form4-09182026_040901.xml
Open SEC.gov